Zymeworks (ZYME) Operating Leases (2021 - 2026)

Zymeworks (ZYME) has 6 years of Operating Leases data on file, last reported at $13.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 25.46% year-over-year to $13.8 million; the trailing twelve-month figure through Mar 2026 stood at $13.8 million (down 25.46% YoY), and the FY2025 full-year result was $14.8 million, down 20.17% from the prior year.
• Operating Leases retreated to $13.8 million in Q1 2026, from $14.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $30.1 million in Q3 2022 to a low of $13.8 million in Q1 2026.
• A 5-year average of $21.6 million and a median of $20.0 million in 2024 frame the typical range for Operating Leases.
• Peak annual rise in Operating Leases reached 5.87% in 2024, while the deepest fall reached 34.52% in 2024.
• Tracing ZYME's Operating Leases over 5 years: stood at $28.0 million in 2022, then retreated by 4.42% to $26.8 million in 2023, then slumped by 30.72% to $18.5 million in 2024, then retreated by 20.17% to $14.8 million in 2025, then dropped by 6.98% to $13.8 million in 2026.
• Business Quant data shows ZYME's Operating Leases at $13.8 million in Q1 2026, $14.8 million in Q4 2025, and $15.5 million in Q3 2025.